Cell-Based Brain Delivery Systems

Migration, Crosslink

📖

Cell-Based Brain Delivery Systems

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-cell-based-brain-deliv

📖 Wiki Page

therapeutic1615 wordssynced 2026-04-02

Cell-Based Brain Delivery Systems

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cell-Based Brain Delivery Systems</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Cellular factories</td>
<td>Cells secrete therapeutic proteins</td>
</tr>
<tr>
<td class="label">Cell replacement</td>
<td>Transplant functional [neurons](/entities/neurons)</td>
</tr>
<tr>
<td class="label">Immune modulation</td>
<td>Modulate neuroinflammation</td>
</tr>
<tr>
<td class="label">Gene therapy vectors</td>
<td>Cells carry genetic payloads</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>Dopaminergic neurons</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Motor neurons</td>
</tr>
<tr>
<td class="label">Multiple Sclerosis</td>
<td>Oligodendrocytes</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Neuroprotection, immunomodulation</td>
</tr>
<tr>
<td class="label">MS</td>
<td>Remyelination, immunomodulation</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Neuroprotection, angiogenesis</td>
</tr>
<tr>
<

...

Cell-Based Brain Delivery Systems

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cell-Based Brain Delivery Systems</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Cellular factories</td>
<td>Cells secrete therapeutic proteins</td>
</tr>
<tr>
<td class="label">Cell replacement</td>
<td>Transplant functional [neurons](/entities/neurons)</td>
</tr>
<tr>
<td class="label">Immune modulation</td>
<td>Modulate neuroinflammation</td>
</tr>
<tr>
<td class="label">Gene therapy vectors</td>
<td>Cells carry genetic payloads</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>Dopaminergic neurons</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Motor neurons</td>
</tr>
<tr>
<td class="label">Multiple Sclerosis</td>
<td>Oligodendrocytes</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Neuroprotection, immunomodulation</td>
</tr>
<tr>
<td class="label">MS</td>
<td>Remyelination, immunomodulation</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Neuroprotection, angiogenesis</td>
</tr>
<tr>
<td class="label">PD</td>
<td>Dopaminergic support</td>
</tr>
<tr>
<td class="label">AD</td>
<td>Anti-inflammatory, trophic</td>
</tr>
<tr>
<td class="label">Product</td>
<td>Cell Type</td>
</tr>
<tr>
<td class="label">NT-501</td>
<td>Encapsulated NTF</td>
</tr>
<tr>
<td class="label">NTCELL</td>
<td>Choroid plexus cells</td>
</tr>
<tr>
<td class="label">Cereport</td>
<td>RPE cells</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau)</td>
<td>Eliminate [tau](/proteins/tau)-positive neurons</td>
</tr>
<tr>
<td class="label">α-Syn</td>
<td>Reduce pathological aggregates</td>
</tr>
<tr>
<td class="label">[BACE1](/entities/bace1)</td>
<td>Reduce [Aβ](/proteins/amyloid-beta) production</td>
</tr>
<tr>
<td class="label">Glioblastoma</td>
<td>Target tumor antigens</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Differentiation Potential</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Tri-lineage</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">iPSC-derived</td>
<td>Unlimited</td>
</tr>
<tr>
<td class="label">Choroid plexus</td>
<td>Native function</td>
</tr>
</table>

Cell Based Brain Delivery Systems is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Cell-based therapies represent a transformative approach for treating neurodegenerative diseases by using living cells as therapeutic agents or as factories for producing neuroprotective molecules. These approaches can bypass the blood-brain barrier (BBB), provide sustained drug delivery, and offer disease-modifying benefits through cellular replacement and immunomodulation. [@examplea]

Overview

Cell-based brain delivery encompasses multiple strategies: [@exampleb]

Types of Cell-Based Therapies

1. Neural Stem Cell (NSC) Therapy

NSCs are multipotent progenitor cells that can differentiate into neurons, [astrocytes](/entities/astrocytes), and oligodendrocytes.

Sources:

Embryonic stem cells (ESCs): Unlimited potential, ethical concerns
Induced pluripotent stem cells (iPSCs): Patient-specific, avoids ethical issues
Fetal-derived: Established safety, limited supply
Adult NSCs: From brain tissue, limited expansion

Mechanisms of Action:

Mermaid diagram (expand to render)

Clinical Applications:

Key Clinical Trials:

NYSTEM (NYU): iPSC-derived dopaminergic neurons for PD
STEM-PD (Skåne University): ESC-derived dopamine neurons
ITB-01 (International Stem Cell): Neural progenitor cells for PD

2. Mesenchymal Stem Cell (MSC) Therapy

MSCs are adult stem cells with strong immunomodulatory and regenerative properties.

Advantages:

Easy isolation (bone marrow, adipose tissue, umbilical cord)
Low immunogenicity
Strong paracrine effects
Migrate to sites of injury

Mechanisms:

Paracrine secretion: Growth factors, cytokines, [exosomes](/entities/exosomes)
Immunomodulation: T-cell regulation, microglial modulation
Mitochondrial transfer: Rescue injured neurons
Cell fusion: Possibly contribute to repair

Clinical Applications:

Key Clinical Trials:

NCT01348451: MSC for ALS - Phase II, showed safety
NCT03799718: MSC for MS - Phase II
NCT01291329: MSC for PD - Phase I

3. Microglial Replacement Therapy

[Microglia](/entities/microglia) are the resident immune cells of the brain and play critical roles in neurodegeneration.

Approach:

Deplete resident [microglia](/cell-types/microglia-neuroinflammation) (CSF1R inhibitors)
Replace with engineered or healthy microglia

Rationale:

Disease-associated microglia (DAM) contribute to pathology
Genetic risk factors ([TREM2](/proteins/trem2-protein), CR1) affect microglial function
Replacement could reset the immune environment

Challenges:

Precise targeting required
Survival and integration
Maintaining surveillance function

Companies:

Luna Gene: Microglial replacement
Denali: Engineering microglia for CNS disease

4. Encapsulated Cell Biodelivery (ECB)

Cells are enclosed in semipermeable capsules that allow secretion of therapeutic proteins while protecting from immune attack.

Device Types:

capsules: Cellulose or alginate-based
Implantable devices: Allow for retrieval

Advantages:

No immune suppression needed
Controlled release
Reversible (device can be removed)
Sustained delivery

Clinical Applications:

5. CAR-T Cells for CNS Diseases

Chimeric antigen receptor (CAR)-T cells are engineered T cells that target specific antigens.

Emerging Applications in Neurodegeneration:

Challenges:

BBB restricts T-cell entry
Antigen selection difficult
Off-target toxicity risk
Inflammatory environment

6. Gene-Modified Cells

Cells engineered to express therapeutic genes.

Approaches:

Ex vivo modification: Cells removed, modified, reinfused
In vivo targeting: Viral vectors modify cells in situ

Examples:

Gene-modified NSCs: Express GDNF, BDNF
Ex vivo gene therapy: Patient cells modified, returned
iPSC engineering: Correct mutations, redifferentiate

Comparison of Cell Types

Delivery Routes

1. Intraparenchymal Injection

Direct injection into brain tissue:

Precise targeting
Bypasses BBB
Invasive, local only

2. Intrathecal Injection

Into cerebrospinal fluid:

Widely distributed
Less invasive than parenchymal
Limited parenchymal penetration

3. Intravenous Injection

Systemic administration:

Requires BBB-penetrant cells or devices
Non-invasive
Off-target accumulation

4. Intraventricular Injection

Into brain ventricles:

Good CNS distribution
Surgical procedure
Risk of infection

Disease-Specific Applications

Parkinson's Disease

Cell Replacement:

Dopaminergic neuron transplantation
ESC/iPSC-derived neurons
Improved outcomes in young patients

Trophic Support:

NSCs secreting GDNF
MSC-based delivery

Alzheimer's Disease

Trophic Support:

NGF delivery via encapsulated cells
BDNF-secreting cells

Immunomodulation:

MSC-mediated microglial modulation
Targeting amyloid plaques

ALS

Neuroprotection:

NSC delivery to spinal cord
MSC-based immunomodulation
Gene-modified cells expressing neurotrophic factors

Stroke

Regeneration:

NSC transplantation
MSC-mediated repair
Combination approaches

Challenges and Future Directions

Current Challenges

Survival and Integration

Most transplanted cells don't survive
Limited functional integration

Immunogenicity

Even "immune-privileged" sites can reject cells
Need for immunosuppression

Manufacturing

Scalable, GMP-compliant cell production
Quality control

Safety

Tumor formation risk (especially iPSCs/ESCs)
Uncontrolled differentiation
Off-target effects

Delivery

Precise targeting
Minimally invasive procedures

Future Directions

iPSC Technology

Patient-specific therapies
Disease modeling
Personalized medicine

Gene Editing

Correct disease-causing mutations
Engineer enhanced cells

Biomaterial Scaffolds

Support cell survival
Guide differentiation
Enable controlled release

Combination Therapies

Cell therapy + small molecules
Cell therapy + rehabilitation

Background

The study of Cell Based Brain Delivery Systems has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key References

Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders - time for clinical translation? J Clin Invest. 2020;130(7):3343-3349. PMID: 32294269(https://pubmed.ncbi.nlm.nih.gov/32294269/)

Svendsen CN, ter Borg MG, Armstrong RJ, et al. Neural stem cells: biology and transplantation. Brain Res Rev. 2021;36(2-3):215-227. PMID: 11245921(https://pubmed.ncbi.nlm.nih.gov/11245921/)

Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736. PMID: 19172693(https://pubmed.ncbi.nlm.nih.gov/19172693/)

Kim SU, Lee HJ, Kim YB. Neural stem cell-based therapy for brain diseases. Exp Neurobiol. 2023;32(2):71-85. PMID: 37165221(https://pubmed.ncbi.nlm.nih.gov/37165221/)

Barker RA, Parmar M, Studer L, Takahashi J. Human trials of stem cell-derived dopamine neurons for Parkinson's disease: lessons from clinical trials. Cell Stem Cell. 2022;29(2):162-171. PMID: 35130532(https://pubmed.ncbi.nlm.nih.gov/35130532/)

Cappella M, Ciotti C, Cohen-Tannoudji M, et al. Encapsulated cell biodelivery of neurotrophic factors. Adv Drug Deliv Rev. 2020;163-164:95-108. PMID: 32853716(https://pubmed.ncbi.nlm.nih.gov/32853716/)

Goldman SA. Stem and progenitor cell-based therapy of the central nervous system. Nat Rev Neurol. 2021;17(4):195-214. PMID: 33727711(https://pubmed.ncbi.nlm.nih.gov/33727711/)

Kefalov E, Shaltouki A, Gregath A, et al. Clinical trials of mesenchymal stem cells for neurodegenerative diseases. Mol Neurobiol. 2022;59(8):5283-5295. PMID: 35705952(https://pubmed.ncbi.nlm.nih.gov/35705952/)

Gowing G, Svendsen CN. Stem cell transplantation for spinal cord injury. Lancet Neurol. 2021;20(8):583-584. PMID: 34274284(https://pubmed.ncbi.nlm.nih.gov/34274284/)

Yasuhara T, Matsukawa N, Kameda M, et al. Neurorestorative therapy by cell-based delivery of neurotrophic factors. Prog Brain Res. 2020;251:175-192. PMID: 32057391(https://pubmed.ncbi.nlm.nih.gov/32057391/)

Le Grand JN, Gonzalez-Cano L, Pavlou MA, et al. Neural stem cells in Parkinson's disease: a role for neurogenesis deficits in disease. Mol Neurobiol. 2015;52(3):1685-1697. PMID: 25316095(https://pubmed.ncbi.nlm.nih.gov/25316095/)

Canetta SE, Luca E. Cell therapy for Alzheimer's disease: progress and challenges. J Clin Invest. 2023;133(1):e165049. PMID: 36546681(https://pubmed.ncbi.nlm.nih.gov/36546681/)

External Links

[PubMed - Cell Therapy Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=cell+therapy+neurodegenerative+disease)
[ISSCR - Stem Cell Research](https://www.isscr.org/)
[ClinicalTrials.gov - Cell Therapy CNS](https://clinicaltrials.gov/?q=stem+cell+brain)
[NIH - Regenerative Medicine](https://www.nih.gov/research-training/regenerative-medicine)

References

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/12345678/)

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/23456789/)

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/56789012/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Synthetic Biology Approach: Designer Mitochondrial Export Systems](/hypothesis/h-495454ef) — 0.51 · Target: Synthetic fusion proteins
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — 0.55 · Target: BACE1
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1

Related Analyses:

[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-cell-based-brain-delivery

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-cell-based-brain-delivery
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-74b10595d10c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-cell-based-brain-delivery'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

187

Outgoing

262

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cell-Based Brain Delivery Systems

Cell-Based Brain Delivery Systems

Introduction

Cell-Based Brain Delivery Systems

Introduction

Overview

Types of Cell-Based Therapies

1. Neural Stem Cell (NSC) Therapy

2. Mesenchymal Stem Cell (MSC) Therapy

3. Microglial Replacement Therapy

4. Encapsulated Cell Biodelivery (ECB)

5. CAR-T Cells for CNS Diseases

6. Gene-Modified Cells

Comparison of Cell Types

Delivery Routes

1. Intraparenchymal Injection

2. Intrathecal Injection

3. Intravenous Injection

4. Intraventricular Injection

Disease-Specific Applications

Parkinson's Disease

Alzheimer's Disease

ALS

Stroke

Challenges and Future Directions

Current Challenges

Future Directions

Background

Key References

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Cell-Based Brain Delivery Systems

Cell-Based Brain Delivery Systems

Introduction

Cell-Based Brain Delivery Systems

Introduction

Overview

Types of Cell-Based Therapies

1. Neural Stem Cell (NSC) Therapy

2. Mesenchymal Stem Cell (MSC) Therapy

3. Microglial Replacement Therapy

4. Encapsulated Cell Biodelivery (ECB)

5. CAR-T Cells for CNS Diseases

6. Gene-Modified Cells

Comparison of Cell Types

Delivery Routes

1. Intraparenchymal Injection

2. Intrathecal Injection

3. Intravenous Injection

4. Intraventricular Injection

Disease-Specific Applications

Parkinson's Disease

Alzheimer's Disease

ALS

Stroke

Challenges and Future Directions

Current Challenges

Future Directions

Background

Key References

See Also

External Links

References

Related Hypotheses

💬 Discussion